GLY-220

About Glycadia Pharmaceuticals

Glycadia Pharmaceuticals is targeting a critical unmet need in diabetes care by developing first-in-class therapies that directly address the root cause of diabetic complications: excess glycation of proteins. The company's lead asset, GLY-230, has completed Phase 1 trials and is being prepared for Phase 2 studies in diabetic nephropathy, positioning it as a potential disease-modifying agent. With a pipeline that includes both small molecules and monoclonal antibodies for microvascular and macrovascular diseases, Glycadia is operating in a massive market with over 100 million affected individuals in the US alone, where current standard of care fails to adequately control complications for the majority of patients.

Therapeutic Areas

Other Diabetic macrovascular disease Drugs